Calcium channel blockers and outcomes in older patients with heart failure and preserved ejection fraction

Circulation: Heart Failure

Volumn 7, Issue 6, 2014, Pages 945-952

  Patel, Kanan ^a   Fonarow, Gregg C ^b   Ahmed, Momanna ^c,e   Morgan, Charity ^d,e   Kilgore, Meredith ^d,e   Love, Thomas E ^f   Deedwania, Prakash ^a   Aronow, Wilbert S ^g   Anker, Stefan D ^h   Ahmed, Ali ⁱ  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Department of Biostatistics ^*  (United States)

^d Department of Health Care Organization and Policy ^*  (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g NEW YORK MEDICAL COLLEGE   (United States)

^h UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

ⁱ VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Calcium channel blockers; Heart failure

Indexed keywords

AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT;

AGED; ARTICLE; CARDIOVASCULAR MORTALITY; COMORBIDITY; CONTROLLED STUDY; DRUG FATALITY; DRUG USE; FEMALE; HAZARD RATIO; HEART EJECTION FRACTION; HEART FAILURE; HOSPITALIZATION; HUMAN; HUMAN EXPERIMENT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; PROPENSITY SCORE; SENSITIVITY ANALYSIS; VERY ELDERLY; HEART STROKE VOLUME; MORTALITY; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; CALCIUM CHANNEL BLOCKERS; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; PROPENSITY SCORE; STROKE VOLUME; TREATMENT OUTCOME;

EID: 84925716351     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.114.001301     Document Type: Article

References (42)

1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ, Sorlie PD, Sotoodehnia N, Turan TN, Virani SS, Wong ND, Woo D, Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012;125:e2-e220.
2. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med. 2009;360:1418-1428.
3. Kitzman DW, Gardin JM, Gottdiener JS, Arnold A, Boineau R, Aurigemma G, Marino EK, Lyles M, Cushman M, Enright PL; Cardiovascular Health Study Research Group. Importance of heart failure with preserved systolic function in patients > or = 65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol. 2001;87:413-419.
4. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:e391-e479.
5. Oghlakian GO, Sipahi I, Fang JC. Treatment of heart failure with preserved ejection fraction: have we been pursuing the wrong paradigm? Mayo Clin Proc. 2011;86:531-539.
6. Hung MJ, Cherng WJ, Kuo LT, Wang CH. Effect of verapamil in elderly patients with left ventricular diastolic dysfunction as a cause of congestive heart failure. Int J Clin Pract. 2002;56:57-62.
7. Setaro JF, Zaret BL, Schulman DS, Black HR, Soufer R. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol. 1990;66:981-986.
8. Rosenbaum PR, Rubin DB. The central role of propensity score in observational studies for causal effects. Biometrika. 1983;70:41-55.
9. Rubin DB. Using propensity score to help design observational studies: application to the tobacco litigation. Health Serv Outcomes Res Methodol. 2001;2:169-188.
10. Austin PC. Primer on statistical interpretation or methods report card on propensity-score matching in the cardiology literature from 2004 to 2006: a systematic review. Circ Cardiovasc Qual Outcomes. 2008;1:62-67.
11. Michels KB, Braunwald E. Estimating treatment effects from observational data: dissonant and resonant notes from the SYMPHONY trials. JAMA. 2002;287:3130-3132.
12. Fonarow GC, Abraham WT, Albert NM, Gattis WA, Gheorghiade M, Greenberg B, O'Connor CM, Yancy CW, Young J. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. Am Heart J. 2004;148:43-51.
13. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O'Connor CM, Pieper K, Sun JL, Yancy C, Young JB; OPTIMIZE-HF Investigators and Hospitals. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA. 2007;297:61-70.
14. Gheorghiade M, Abraham WT, Albert NM, Greenberg BH, O'Connor CM, She L, Stough WG, Yancy CW, Young JB, Fonarow GC; OPTIMIZE-HF Investigators and Coordinators. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA. 2006;296:2217-2226.
15. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, O'Connor CM, Sun JL, Yancy CW, Young JB; OPTIMIZE-HF Investigators and Hospitals. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007;50:768-777.
16. Zhang Y, Kilgore ML, Arora T, Mujib M, Ekundayo OJ, Aban IB, Feller MA, Desai RV, Love TE, Allman RM, Fonarow GC, Ahmed A. Design and rationale of studies of neurohormonal blockade and outcomes in diastolic heart failure using OPTIMIZE-HF registry linked to Medicare data. Int J Cardiol. 2013;166:230-235.
17. Ray WA. Evaluating medication effects outside of clinical trials: newuser designs. Am J Epidemiol. 2003;158:915-920.
18. Hernán MA, Hernández-Díaz S, Robins JM. A structural approach to selection bias. Epidemiology. 2004;15:615-625.
19. Danaei G, Tavakkoli M, Hernán MA. Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. Am J Epidemiol. 2012;175:250-262.
20. Patel K, Fonarow GC, Kitzman DW, Aban IB, Love TE, Allman RM, Gheorghiade M, Ahmed A. Angiotensin receptor blockers and outcomes in real-world older patients with heart failure and preserved ejection fraction: a propensity-matched inception cohort clinical effectiveness study. Eur J Heart Fail. 2012;14:1179-1188.
21. Deedwania PC, Ahmed MI, Feller MA, Aban IB, Love TE, Pitt B, Ahmed A. Impact of diabetes mellitus on outcomes in patients with acute myocardial infarction and systolic heart failure. Eur J Heart Fail. 2011;13:551-559.
22. Filippatos GS, Ahmed MI, Gladden JD, Mujib M, Aban IB, Love TE, Sanders PW, Pitt B, Anker SD, Ahmed A. Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data. Eur Heart J. 2011;32:712-720.
23. Patel K, Fonarow GC, Kitzman DW, Aban IB, Love TE, Allman RM, Gheorghiade M, Ahmed A. Aldosterone antagonists and outcomes in real-world older patients with heart failure and preserved ejection fraction. JACC Heart Fail. 2013;1:40-47.
24. Ahmed A, Fonarow GC, Zhang Y, Sanders PW, Allman RM, Arnett DK, Feller MA, Love TE, Aban IB, Levesque R, Ekundayo OJ, Dell'Italia LJ, Bakris GL, Rich MW. Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease. Am J Med. 2012;125:399-410.
25. Ahmed A, Perry GJ, Fleg JL, Love TE, Goff DC Jr, Kitzman DW. Outcomes in ambulatory chronic systolic and diastolic heart failure: a propensity score analysis. Am Heart J. 2006;152:956-966.
26. Ahmed MI, White M, Ekundayo OJ, Love TE, Aban I, Liu B, Aronow WS, Ahmed A. A history of atrial fibrillation and outcomes in chronic advanced systolic heart failure: a propensity-matched study. Eur Heart J. 2009;30:2029-2037.
27. Guichard JL, Desai RV, Ahmed MI, Mujib M, Fonarow GC, Feller MA, Ekundayo OJ, Bittner V, Aban IB, White M, Aronow WS, Love TE, Bakris GL, Zieman SJ, Ahmed A. Isolated diastolic hypotension and incident heart failure in older adults. Hypertension. 2011;58:895-901.
28. Curtis LH, Greiner MA, Hammill BG, DiMartino LD, Shea AM, Hernandez AF, Fonarow GC. Representativeness of a national heart failure quality-of-care registry: comparison of OPTIMIZE-HF and non-OPTIMIZE-HF Medicare patients. Circ Cardiovasc Qual Outcomes. 2009;2:377-384.
29. Rosenbaum PR. Sensitivity to hidden bias. In: Rosenbaum PR, ed. Observational Studies. New York: Springer-Verlag; 2002:105-170.
30. Costanzo P, Perrone-Filardi P, Petretta M, Marciano C, Vassallo E, Gargiulo P, Paolillo S, Petretta A, Chiariello M. Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175,634 patients. J Hypertens. 2009;27:1136-1151.
31. O'Connor CM, Carson PE, Miller AB, Pressler ML, Belkin RN, Neuberg GW, Frid DJ, Cropp AB, Anderson S, Wertheimer JH, DeMets DL. Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective Randomized Amlodipine Survival Evaluation. Am J Cardiol. 1998;82:881-887.
32. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer JH, Cropp AB, DeMets DL. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med. 1996;335:1107-1114.
33. Hager WD, Davis BR, Riba A, Moye LA, Wun CC, Rouleau JL, Lamas GA, Pfeffer MA. Absence of a deleterious effect of calcium channel blockers in patients with left ventricular dysfunction after myocardial infarction: The SAVE Study Experience. SAVE Investigators. Survival and Ventricular Enlargement. Am Heart J. 1998;135:406-413.
34. Cleophas TJ, van Marum R. Meta-analysis of efficacy and safety of second-generation dihydropyridine calcium channel blockers in heart failure. Am J Cardiol. 2001;87:487-90, A7.
35. Bonow RO, Dilsizian V, Rosing DR, Maron BJ, Bacharach SL, Green MV. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short-and long-term effects. Circulation. 1985;72:853-864.
36. Figulla HR, Gietzen F, Zeymer U, Raiber M, Hegselmann J, Soballa R, Hilgers R. Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy. Results of the Diltiazem in Dilated Cardiomyopathy Trial. Circulation. 1996;94: 346-352.
37. Cheng CP, Pettersson K, Little WC. Effects of felodipine on left ventricular systolic and diastolic performance in congestive heart failure. J Pharmacol Exp Ther. 1994;271:1409-1417.
38. Packer M, Carson P, Elkayam U, Konstam MA, Moe G, O'Connor C, Rouleau JL, Schocken D, Anderson SA, DeMets DL; PRAISE-2 Study Group. Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2). JACC Heart Fail. 2013;1:308-314.
39. Banach M, Bhatia V, Feller MA, Mujib M, Desai RV, Ahmed MI, Guichard JL, Aban I, Love TE, Aronow WS, White M, Deedwania P, Fonarow G, Ahmed A. Relation of baseline systolic blood pressure and long-term outcomes in ambulatory patients with chronic mild to moderate heart failure. Am J Cardiol. 2011;107:1208-1214.
40. Desai RV, Banach M, Ahmed MI, Mujib M, Aban I, Love TE, White M, Fonarow G, Deedwania P, Aronow WS, Ahmed A. Impact of baseline systolic blood pressure on long-term outcomes in patients with advanced chronic systolic heart failure (insights from the BEST trial). Am J Cardiol. 2010;106:221-227.
41. Butler J, Arbogast PG, Daugherty J, Jain MK, Ray WA, Griffin MR. Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge. J Am Coll Cardiol. 2004;43:2036-2043.
42. Curtis LH, Mi X, Qualls LG, Check DK, Hammill BG, Hammill SC, Heidenreich PA, Masoudi FA, Setoguchi S, Hernandez AF, Fonarow GC. Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure. Am Heart J. 2013;165:979-986.e1.